Resmed Inc (RMD) Return on Assets ROA from the first quarter of 2026 to first quarter of 2026 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Resmed Inc   (NYSE: RMD)


Resmed Inc 's ROA from the first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Resmed Inc 's ROA in the first quarter of 2026?
Resmed Inc achieved a return on average assets (ROA) of 18.06 % in its first quarter of 2026, this is above RMD's average return on assets of 13.38%.
Resmed Inc s assets during the 12 months ending in the first quarter of 2026 are valued at $8 billion

ROA has improved compared to 17.3% in the fourth quarter of 2026, due to net income growth.

However, within the Healthcare sector 49 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 265, from total ROA ranking in the fourth quarter of 2026 at 290.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
I. Quarter		 (Jun 30 2026)
IV. Quarter		 (Mar 31 2026)
III. Quarter		 (Dec 31 2025)
II. Quarter		 (Sep 30 2025)
I. Quarter
Y / Y Total Assets Change 0.78 % 13.4 % 18.44 % 17.24 % 15.31 %
Y / Y Net Income Change 20.05 % 0.98 % 9.23 % 13.92 % 11.94 %
Net Income (TTM) in million 1,593 1,523 1,520 1,486 1,438
Return On Assets (TTM) 18.06 % 17.3 % 17.8 % 18.13 % 18.3 %
RMD's Total Ranking # 265 # 290 # 262 # 260 # 267
Total Assets (TTM) in million 8,212 9,084 8,784 9,209 8,149
Seq. Total Assets Change -9.6 % 3.41 % -4.61 % 13.02 % 1.73 %
Seq. Net Income Change 9.12 % -3.84 % 1.56 % 12.64 % -8.21 %

RMD's 5 Years Annual ROA >> Back to RMD Management Effectiveness >> Compare RMD ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 8
Sector # 50
Overall # 247

Return On Assets Statistics
High Average Low
18.78 %
13.38 %
6.12 %
  (Jun 30 2013)



  News about Resmed Inc Return on Assets ROA

ResMeds Forward-Thinking 2030 Strategy: A Robust Blueprint for Sustainable Growth and Shareholder Value

In a significant move aimed at securing its position as a leader in the healthcare sector, ResMed (NYSE: RMD, ASX: RMD) unveiled its ambitious 2030 Strategy during an Investor Day event held in New York City on September 30, 2024. This new initiative is designed to drive growth, enhance profitability, and maximize shareholder returns, reflecting ResMed s commitment to innovation and operational excellence.The backbone of ResMed’s 2030 Strategy lies in its comprehensive approach to product and technology innovation, which will serve as a catalyst for accelerated growth. The company has set an ambitious target to help more than 500 million people around the globe achieve their full health potential by the year 2030. This goal is underpinned by ResMed’s continuous investment in cutting-edge technologies designed to improve patient outcomes and streamline healthcare processes.



Financial Statements
Resmed Inc 's Assets $ 8,212 million RMD's Balance sheet
Resmed Inc 's Income $ 418 million Quarterly RMD's Income Statement
RMD's Income by Division See RMD's Income by Division



Annual Return On Assets (Jun 30 2026)
FY 2026		 (Jun 30 2025)
FY 2025		 (Jun 30 2024)
FY 2024		 (Jun 30 2023)
FY 2023		 (Jun 30 2022)
FY 2022
Y / Y Total Assets Change 21.96 % 19.14 % 1.45 % 33.46 % 7.87 %
Total Assets in million 9,769 8,010 6,723 6,627 4,966
Y / Y Net Income Change 8.75 % 37.2 % 13.75 % 15.15 % 64.26 %
Net Income in million 1,523 1,401 1,021 898 779
Annual Return On Assets 15.59 % 17.49 % 15.19 % 13.54 % 15.7 %

RMD's 5 Years Annual ROA >> Back to RMD Management Effectiveness >> Compare RMD ROA to its Competitors



Comment on RMD's ROA in the fiscal year ending 2026
In the fiscal year 2026 ROA deteriorated to 15.59 %, despite annual net income growth of 8.75 % to $1,523.29 million, from $1,400.72 million a year ago, as RMD's assets increase to $9,768.77 million, by 8.75 %.


More Return On Assets Ratios
RMD's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RMD's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RMD's Competitors
Subscribers only: Roa for Resmed Inc 's Suppliers
Subscribers only: Return On Assets for RMD's Customers

You may also want to know
RMD's Roi RMD's Inventory Turnover Ratio RMD's Growth Rates RMD's Dividend Comparisons
RMD's Profitability Ratios RMD's Asset Turnover Ratio RMD's Dividend Growth
RMD's Roe RMD's Valuation Ratios RMD's Financial Strength Ratios RMD's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Alnylam Pharmaceuticals Inc   46.08 %
Ironwood Pharmaceuticals inc   42.53 %
Aurinia Pharmaceuticals Inc   40.63 %
Nurix Therapeutics Inc   38.61 %
Indivior Pharmaceuticals Inc   36.35 %
Rallybio Corporation  34.55 %
Idexx Laboratories Inc  34.05 %
Zevra Therapeutics Inc   26.33 %
Caredx Inc   25.74 %
Medpace Holdings Inc   24.47 %
Acadia Pharmaceuticals Inc   21.60 %
Standard Biotools Inc   21.56 %
Eli Lilly And Company  21.24 %
Iradimed Corporation  20.89 %
Resmed Inc   18.67 %
Alector Inc   18.37 %
Corcept Therapeutics Inc  18.09 %
Chemed Corporation  17.73 %
Halozyme Therapeutics Inc   17.26 %
Pro dex Inc   16.75 %
Denali Therapeutics Inc   16.42 %
Krystal Biotech Inc   15.48 %
West Pharmaceutical Services Inc   15.47 %
Dexcom Inc   15.47 %
Intuitive Surgical Inc   14.71 %
Vertex Pharmaceuticals Inc  14.16 %
Neurocrine Biosciences Inc   13.69 %
Illumina Inc   13.43 %
Healthcare Services Group Inc   12.79 %
Kiniksa Pharmaceuticals International Plc  12.64 %

Date modified: 2026-10-31T10:01:09+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.